43 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
, ultimately serving on the Pharma Executive Committee as Global Head of Product & Portfolio Strategy and then Head of Pharma Region Europe from January 2017 … was responsible for fundraising and overall corporate strategy. From April 2018 until November 2021, Mr. Somaiya served as the Chief Financial Officer
8-K
EX-99.1
NAMS
NewAmsterdam Pharma Company NV
9 May 24
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
8:00am
organization as we execute our multi-pronged clinical development strategy for obicetrapib and begin to prepare for a global launch,” said Michael … and commercial strategy at our R&D Day on May 16th and, if our Phase 3 program is successful and regulatory approval is received, to delivering obicetrapib
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
Related to Our Business and Strategy
We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may … strategy, and operations;
our ability to obtain, protect and enforce our intellectual property rights with respect to obicetrapib; and
our ability
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
as Global Head of Product & Portfolio Strategy and then Head of Pharma Region Europe from January 2017 until January 2022. While at Novartis, Ms. van … strategy. From April 2018 until November 2021, Mr. Somaiya served as the Chief Financial Officer of TCR2 Therapeutics, Inc. (“TCR2”) where he
POS AM
NAMS
NewAmsterdam Pharma Company NV
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
not exercise such rights until after they have consulted the Board of Directors. If exercising such rights may result in a change in our strategy … , the Board of Directors is charged with the management of the Company, which includes setting our policies and strategy, subject to the restrictions
424B3
wfu p18y1vh6zf5m4ba
12 Mar 24
Prospectus supplement
4:18pm
POS AM
scqzt3 pkibq3exnlzvu
28 Feb 24
Prospectus update (post-effective amendment)
5:01pm
10-K
u91o06x 2w7hf1n9hah
28 Feb 24
Annual report
8:00am
10-K
EX-4.4
hvjiuyqhdl2
28 Feb 24
Annual report
8:00am
424B5
t9pjcr2w 4kwguchuf
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
v0zoy
13 Feb 24
Prospectus supplement for primary offering
5:19pm
F-3
wte07grqb tsyu
7 Dec 23
Shelf registration (foreign)
4:16pm
6-K
EX-99.1
ep9j l2slx3
25 Sep 23
Current report (foreign)
8:10am
424B3
545uzgk
15 Aug 23
Prospectus supplement
4:52pm
6-K
EX-99.2
btdu23d
14 Aug 23
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
4:52pm
POS AM
dx3hssu4
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
7splxvkusc0u
7 Aug 23
Research and development expenses
7:24am
424B3
18r ou4bjr6jo499ud
9 Jun 23
Prospectus supplement
9:43pm
6-K
EX-99.1
epni6
9 Jun 23
Current report (foreign)
9:39pm
424B3
mmgrpo r6pwvkarg
8 Jun 23
Prospectus supplement
5:01pm